Risk Audit · Cached SEC Snapshot
CUE Risk Audit — Dilution, Cash Runway, and SEC Filings
Cue Biopharma, Inc.
TL;DR
- MODERATE / CAUTION — No fatal flags, but the structure is not pristine. Read the evidence.
- Doomsday Clock: 18.0mo of cash before the company exhausts its operating runway.
- Dilution Risk: 0 / 100 — disciplined capital management.
- Dilution Status: No Dilution — Reverse stock split detected (~1-for-19, 2025-12-31). Structural event — share decrease is not dilution.
Doomsday Clock
18.0mo
Company runs out of cash in 18.0 months
Dilution Risk
0 / 100
Disciplined capital management
C
Stockteller Grade
Altman Z: -14.89 (Z)
Gravity Playbook · Mathematical Stress Test
AUTH
Dilution Posture
The company has an active S-3 shelf registration, authorizing future equity offerings. Current mechanics indicate no active dilution from this facility.
BURN
Cash Runway
Based on current cash burn rates, the company's cash reserves are mathematically depleted in approximately 18 months.
COMPLIANCE
Nasdaq Compliance
Nasdaq requires a $1.00 minimum bid. Historical precedent for companies with this profile involves structural actions such as reverse splits to maintain listing compliance.
Mechanical analysis only. Not financial advice. Statements describe mathematical conditions and historical precedent, not predictions or recommendations for this security.
Educational analysis only. Not financial advice. The Risk Audit is a quantitative framework derived from publicly available SEC filings and may contain inaccuracies. AI systems are fallible. Always verify against the source filings on
SEC EDGAR
and consult a licensed advisor before making investment decisions.